Companies › Bio-Thera Solutions
8 active drug programs in 11 registered trials: 7 Phase 1, 3 Phase 2, 1 Phase 3; Oncology, Ophthalmology, Neurology, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BAT5906 Anti-VEGF monoclonal antibody | – | Phase 3 | Diabetic Macular Edema (DME) | Apr 2027 |
| BAT1308 anti-PD-1 monoclonal antibody | PDCD1 | Phase 2 | Cervical Cancer; Advanced Solid Tumors | Nov 2026 |
| BAT4406F Anti-AQP4 monoclonal antibody | AQP4 | Phase 2 | Optic Neuromyelitis Spectrum Disease; Minimal Change Disease (MCD) | Dec 2027 |
| BAT8008 for Injection Recombinant humanized anti-Trop2 monoclonal antibody conjugated to exatecan | TROP2 | Phase 1 | Advanced Solid Tumors | Nov 2026 |
| BAT6026 Monoclonal antibody | – | Phase 1 | Dermatitis, Atopic | Dec 2026 |
| Pembrolizumab (BAT3306) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Carcinoma, Non-Small-Cell Lung | Feb 2027 |
| BAT1006 for Injection | – | Phase 1 | Advanced Solid Tumors | Feb 2028 |
| BAT8010 for Injection HER2-directed antibody or immunoconjugate | – | Phase 1 | Advanced Solid Tumors | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06341114 | BAT1308 | Phase 1 | Advanced Solid Tumors | Oncology | Nov 2026 |
| NCT06341114 | BAT8008 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Nov 2026 |
| NCT06094179 | BAT6026 | Phase 1 | Dermatitis, Atopic | Immunology | Dec 2026 |
| NCT06123884 | BAT1308 | Phase 2 | Cervical Cancer | Oncology | Jan 2027 |
| NCT07180862 | Pembrolizumab (BAT3306) | Phase 1 | Carcinoma, Non-Small-Cell Lung | Oncology | Feb 2027 |
| NCT07515079 | BAT5906 | Phase 3 | Diabetic Macular Edema (DME) | Ophthalmology | Apr 2027 |
| NCT05620017 | BAT8008 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | May 2027 |
| NCT06044350 | BAT4406F | Phase 2 | Optic Neuromyelitis Spectrum Disease | Neurology | Dec 2027 |
| NCT06376136 | BAT8010 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2028 |
| NCT06376136 | BAT1006 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2028 |
| NCT07499700 | BAT4406F | Phase 2 | Minimal Change Disease (MCD) | Genitourinary | Oct 2030 |
Mabwell (Shanghai) Bioscience Sichuan Baili Pharmaceutical CSPC Megalith Biopharmaceutical CStone Pharmaceuticals TaiRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.